An investigation vaccine for Alzheimer’s disease, ACI-35.030 by AC Immune, induced a potent production of antibodies against toxic forms of tau protein — a Alzheimer’s hallmark — in patients with early stage disease, interim results of an ongoing Phase 1b/2a trial show. “These promising results … will be invaluable as we work to further ACI-35.030’s clinical development and ultimately fulfill the hopes of clinicians and patients for a therapy that could delay, or even prevent, the onset…
You must be logged in to read/download the full post.
The post Vaccine Sparking Immune Reaction Against Toxic Tau Proteins in Trial appeared first on BioNewsFeeds.